Results 1 to 10 of about 729,893 (343)

Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

The Journal of the National Comprehensive Cancer Network, 2022
Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues.
M. von Mehren, J. Kane, M. Agulnik, M. Bui, Janai R. Carr-Ascher, E. Choy, M. Connelly, Sarah Dry, K. Ganjoo, Ricardo J. Gonzalez, A. Holder, J. Homsi, V. Keedy, C. Kelly, Edward Kim, D. Liebner, M. McCarter, Sean V. McGarry, N. Mesko, C. Meyer, A. Pappo, A. Parkes, I. Petersen, S. Pollack, M. Poppe, R. Riedel, S. Schuetze, J. Shabason, J. Sicklick, M. Spraker, M. Zimel, Lisa E Hang, Hema M Sundar, Mary Anne Bergman   +33 more
semanticscholar   +1 more source

Sarcoma classification by DNA methylation profiling

Nature Communications, 2021
Sarcomas are malignant soft tissue and bone tumours affecting adults, adolescents and children. They represent a morphologically heterogeneous class of tumours and some entities lack defining histopathological features.
C. Koelsche, D. Schrimpf, D. Stichel, M. Sill, F. Sahm, D. Reuss, Mirjam Blattner, Barbara C. Worst, C. Heilig, K. Beck, P. Horák, S. Kreutzfeldt, Elke Paff, S. Stark, P. Johann, F. Selt, J. Ecker, D. Sturm, K. Pajtler, A. Reinhardt, A. Wefers, P. Sievers, A. Ebrahimi, A. Suwala, F. Fernández-Klett, B. Casalini, A. Korshunov, V. Hovestadt, F. Kommoss, M. Kriegsmann, M. Schick, M. Bewerunge-Hudler, T. Milde, O. Witt, A. Kulozik, M. Kool, L. Romero-Pérez, T. Grünewald, T. Kirchner, W. Wick, M. Plattén, A. Unterberg, M. Uhl, A. Abdollahi, J. Debus, B. Lehner, C. Thomas, M. Hasselblatt, W. Paulus, C. Hartmann, O. Staszewski, M. Prinz, J. Hench, S. Frank, Y. Versleijen-Jonkers, M. Weidema, T. Mentzel, K. Griewank, E. de Álava, Juan Díaz Martín, M. A. I. Gastearena, K. Chang, S. Low, Adrián Cuevas-Bourdier, M. Mittelbronn, M. Mynarek, S. Rutkowski, U. Schüller, V. Mautner, J. Schittenhelm, J. Serrano, M. Snuderl, R. Büttner, T. Klingebiel, R. Buslei, M. Gessler, P. Wesseling, W. Dinjens, S. Brandner, Z. Jaunmuktane, Iben Lyskjær, P. Schirmacher, A. Stenzinger, B. Brors, H. Glimm, C. Heining, Ò. M. Tirado, Miguel Sáinz-Jaspeado, J. Mora, J. Alonso, X. G. del Muro, S. Moran, M. Esteller, J. Benhamida, M. Ladanyi, E. Wardelmann, C. Antonescu, A. Flanagan, U. Dirksen, P. Hohenberger, D. Baumhoer, W. Hartmann, Christian Vokuhl, U. Flucke, I. Petersen, G. Mechtersheimer, D. Capper, David T. W. Jones, S. Fröhling, S. Pfister, A. von Deimling   +110 more
semanticscholar   +1 more source

Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma

Nature Communications, 2022
There are more than 70 distinct sarcomas, and this diversity complicates the development of precision-based therapeutics for these cancers. Prospective comprehensive genomic profiling could overcome this challenge by providing insight into sarcomas ...
M. Gounder, Narasimhan P. Agaram, S. Trabucco, V. Robinson, Richard A Ferraro, S. Millis, Anita Krishnan, Jessica K. Lee, S. Attia, W. Abida, A. Drilon, Ping Chi, Sandra P D' Angelo, M. Dickson, M. Keohan, C. Kelly, M. Agulnik, S. Chawla, E. Choy, R. Chugh, C. Meyer, P. Myer, Jessica L Moore, R. Okimoto, R. Pollock, V. Ravi, Arun S. Singh, N. Somaiah, A. Wagner, J. Healey, G. Frampton, J. Venstrom, J. Ross, M. Ladanyi, S. Singer, M. Brennan, G. Schwartz, A. Lazar, D. Thomas, R. Maki, W. Tap, Siraj M. Ali, D. Jin   +42 more
semanticscholar   +1 more source

Synovial Sarcoma: A Clinical Review

Current Oncology, 2021
Synovial sarcomas (SS) represent a unique subset of soft tissue sarcomas (STS) and account for 5–10% of all STS. Synovial sarcoma differs from other STS by the relatively young age at diagnosis and clinical presentation.
A. Gazendam, S. Popovic, Sohaib Munir, N. Parasu, David A Wilson, M. Ghert   +5 more
semanticscholar   +1 more source

B cells are associated with survival and immunotherapy response in sarcoma

Nature, 2020
Soft-tissue sarcomas represent a heterogeneous group of cancer, with more than 50 histological subtypes1,2. The clinical presentation of patients with different subtypes is often atypical, and responses to therapies such as immune checkpoint blockade ...
F. Petitprez, A. Reyniès, E. Keung, T. Chen, Cheng-Ming Sun, J. Calderaro, Y. Jeng, Li-Ping Hsiao, L. Lacroix, A. Bougoüin, M. Moreira, Guillaume Lacroix, Ivo Natario, J. Adam, C. Lucchesi, Y. Laizet, M. Toulmonde, M. Burgess, V. Bolejack, D. Reinke, K. Wani, Wei-Lien Wang, A. Lazar, C. Roland, J. Wargo, A. Italiano, C. Sautès-Fridman, H. Tawbi, W. Fridman   +28 more
semanticscholar   +1 more source

Genome-wide CRISPR/Cas9 library screening identified ATM signaling network genes as critical drivers for resistance to ATR inhibition in soft-tissue sarcomas: synthetic lethality and therapeutic implications

Experimental Hematology & Oncology, 2023
Soft-tissue sarcoma (STS) are a heterogeneous group of rare tumors with different biological behavior that are fatal in more than 40% of cases, due to their metastatic evolution and inadequate treatment options. ATR inhibition already showed an activity,
M Spalato-Ceruso, A Laroche-Clary, R Perret, Y Valverde, V Chaire, Marie-Alix Derieppe, V Velasco, A Bourdon, A Italiano   +8 more
doaj   +1 more source

A nomogram for predicting overall survival in patients with low‐grade endometrial stromal sarcoma: A population‐based analysis

Cancer Communications, 2020
Low‐grade endometrial stromal sarcoma (LG‐ESS) is a rare tumor that lacks a prognostic prediction model. Our study aimed to develop a nomogram to predict overall survival of LG‐ESS patients.
Jie Wu, Hui-bo Zhang, Lan Li, M. Hu, Liang Chen, Bin Xu, Q. Song   +6 more
semanticscholar   +1 more source

Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311)

Frontiers in Oncology, 2023
BackgroundIntratumoral injection of talimogene laherparepvec evokes a cytotoxic immune response. Therefore, the combination of talimogene laherparepvec with trabectedin and nivolumab may have synergistic effects in advanced sarcomas.Patients and ...
Sant P. Chawla, Walter Andree Tellez, Hripsime Chomoyan, Chrysler Valencia, Amir Ahari, Nadezhda Omelchenko, Stefan Makrievski, Don A. Brigham, Don A. Brigham, Victoria Chua-Alcala, Doris Quon, Ania Moradkhani, Erlinda M. Gordon, Erlinda M. Gordon   +13 more
doaj   +1 more source

Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment

ESMO Open, 2020
Background Imatinib is the standard first-line therapy in metastatic gastrointestinal stromal tumours (GIST). Investigational multi-kinase inhibitors (MKIs) such as nilotinib, dasatinib or masitinib have been tested as first-line therapies in phase II ...
Etienne Rouleau, Axel Le Cesne, Olivier Mir, Pierre Méeus, Julien Adam, Alice Boilève, Armelle Dufresne, Ali Chamseddine, Elise Nassif, Sarah Dumont, Medhi Brahmi, Marie Karanian, Véronique Haddad, Matthieu Faron, Charles Honoré   +14 more
doaj   +1 more source

Extra medullar Granulocytic sarcoma: a case report of an exceptional localization [PDF]

, 2020
Granulocytic sarcoma is a rare type of tumor composed of extramedullary immature cells. The breast location is very rare; it accounts for less than 8% of cases.
Khaled, Rahal, Malek, Bouhani, Olfa, Adouni, Olfa, Jaidane, Riadh, Chargui, Saida, Sakhri   +5 more
core   +2 more sources